Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylactic cancer vaccines.

Olivera J Finn1, Guido Forni

  • 1Department of Immunology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, W1142 Biomedical Science Tower, Pittsburgh, PA 15261, USA. ojfinn@pitt.edu

Current Opinion in Immunology
|March 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune cell transcriptional profiles from pre-vaccination peripheral blood predict immune response to preventative MUC1 cancer vaccine.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Prospective Examination of Cellular and Soluble Mediators of Immune Dysregulation and Their Association with Lung Cancer Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2025
Same author

A Multicenter Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer.

medRxiv : the preprint server for health sciences·2025
Same author

Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions.

Antibodies (Basel, Switzerland)·2024
Same author

Pre-vaccination transcriptomic profiles of immune responders to the MUC1 peptide vaccine for colon cancer prevention.

Frontiers in immunology·2024
Same author

Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion.

Cancer immunology research·2024

Activating immunity can prevent tumors by targeting specific antigens. This approach leverages a robust immune system for effective cancer immunoprevention, showing promise in preclinical models.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Distinct experimental systems indicate that activating the immune system can prevent tumor development.
  • The immune system is more effective for prevention as it is not suppressed by tumors or treatments and is not tolerant to antigens.
  • Tumor-associated antigens, including overexpressed/mutated proteins and oncogenic receptors, offer rational targets for specific immunoprevention.

Purpose of the Study:

  • To explore the potential of activating immunity for cancer immunoprevention.
  • To identify and utilize specific tumor-associated antigens as targets for preventive vaccines.
  • To evaluate the efficacy of immunoprevention strategies using preclinical models.

Main Methods:

  • Utilizing distinct experimental systems to study immune activation against tumors.

Related Experiment Videos

  • Identifying and characterizing tumor-associated antigens (overexpressed proteins, mutated proteins, mutated oncogenic growth factor receptors).
  • Employing transgenic mouse models to test vaccine strategies based on identified antigens.

    • Main Results:

    • Data suggest that immunity can be successfully activated to prevent tumors.
    • The immune system's state in the absence of tumor burden and treatment is favorable for immunoprevention.
    • Transgenic mouse models show promising results for vaccines targeting specific antigens.

    Conclusions:

    • Immune system activation presents a viable strategy for cancer immunoprevention.
    • Targeting specific tumor-associated antigens is a rational approach for developing preventive vaccines.
    • Preclinical data from mouse models support the future utility of antigen-based vaccines for cancer prevention.